Lifecore settles proxy fight with 22NW, adds four new directors and declassification proposal

LIFECORE BIOMEDICAL, INC. DE

22NW withdraws director nominations and special meeting demand; board declassification proposal at 2023 annual meeting.
Four new directors appointed: Humberto Antunes, Jason Aryeh, Paul Johnson, Matthew Korenberg.
Standstill agreements with 22NW, Legion, Wynnefield through 2025 annual meeting.
Board size to reduce to 8 pre-AGM, expand to 11 post-AGM, then back to 9 by Nov 2024.
Three investor groups collectively own ~43.5% of voting securities on as-converted basis.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Humberto C. Antunes

Director

LFCR · LIFECORE BIOMEDICAL, INC. DE

Filed: July 1, 2024, 7:59 PM ET

On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.

Appointed

Paul H. Johnson

Director

LFCR · LIFECORE BIOMEDICAL, INC. DE

Filed: July 1, 2024, 7:59 PM ET

On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.

Appointed

Matthew Korenberg

Director

LFCR · LIFECORE BIOMEDICAL, INC. DE

Filed: July 1, 2024, 7:59 PM ET

On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Humberto C. Antunes was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.

Action: appointed
Role: Director

Exact text from the filing

On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul H. Johnson was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.

Action: appointed
Role: Director

Exact text from the filing

On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Korenberg was appointed as Director at LIFECORE BIOMEDICAL, INC. DE.

Action: appointed
Role: Director

Exact text from the filing

On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.

View on SEC.gov

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-24-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.